Filing Flows › Hinge Health (HNGE) › R&D spending
Hinge Health (HNGE) R&D spending by quarter
Hinge Health's R&D spending was $37.5M in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 6 quarters it ranged from $30.3M (Q1 2026) to $280M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $37.5M | +10% | +17% |
| Q2 2026 | $34.1M | +12% | -88% |
| Q1 2026 | $30.3M | -7% | — |
| Q4 2025 | $32.8M | +3% | — |
| Q3 2025 | $31.9M | -89% | — |
| Q2 2025 | $280M | — | — |
Q3 2026 at a glance
Hinge Health, Q3 2026: revenue $235M (+52% year over year), operating margin 21.4%, net earnings $57.4M, operating cash flow $115M. The chart follows the revenue to costs, profit and cash.
Questions
What is Hinge Health's R&D spending?
Hinge Health's R&D spending was $37.5M in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Hinge Health's R&D spending changed?
Over the last 6 quarters it ranged from $30.3M (Q1 2026) to $280M (Q2 2025).